109
Participants
Start Date
November 17, 2014
Primary Completion Date
June 14, 2019
Study Completion Date
June 14, 2019
eteplirsen
Eteplirsen 30 mg/kg will be administered as an IV infusion once a week for 96 weeks, followed by a safety extension (not to exceed 48 weeks).
Columbia University Medical Center, New York
University of Rochester Clinical Research Center, Rochester
Children's Hospital of Pittsburgh of UPMC, Pittsburgh
Penn State Hershey Medical Center, Hershey
Children's Hospital of Philadelphia, Philadelphia
Children's National Health System, Washington D.C.
Kennedy Krieger Institute, Baltimore
Levine Childrens Hospital, Carolinas Medical Center, Charlotte
Rare Disease Research Center, Atlanta
Emory University, Atlanta
NW FL Clinical Research Group, LLC, Gulf Breeze
The University of Florida, Powell Gene Therapy Center, Gainesville
Nemours Children's Hospital, Orlando
Vanderbilt University Medical Center, Nashville
Nationwide Children's Hospital, Columbus
Cincinnati Children's Hospital Medical Center (CCHMC), Cincinnati
Children's Hospital of Michigan, Detroit
University of Iowa Children's Hospital, Iowa City
University of Minnesota, Minneapolis
Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago
St. Louis Children's Hospital, St Louis
University of Kansas Medical Center, Kansas City
The University of Texas Southwestern Medical Center, Dallas
Texas Children's Hospital, Houston
Children's Hospital Colorado, Aurora
University of Utah, Salt Lake City
Neuromuscular Research Center, Phoenix
David Geffen School of Medicine at UCLA, Los Angeles
Rady Children's Hospital, U.C. San Diego, San Diego
Stanford University School of Medicine/Medical Center, Stanford
University of California, Davis Medical Center, Sacramento
Shriners Hospital for Children, Portland
Seattle Children's Hospital, Seattle
Connecticut Children's Medical Center, Hartford
Massachusetts General Hospital, Boston
Children's Hospital Boston, Boston
Dartmouth-Hitchcock Medical Center, Lebanon
Sarepta Therapeutics, Inc.
INDUSTRY